Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CONZIP vs ABSTRAL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Tramadol hydrochloride (opioid agonist) and acetaminophen (centrally acting analgesic). Tramadol binds to mu-opioid receptors and inhibits serotonin and norepinephrine reuptake; acetaminophen inhibits cyclooxygenase (COX) and activates descending serotonergic pathways.
Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.
Moderate to moderately severe pain,Pain management in adults
Management of breakthrough pain in cancer patients aged 18 and older who are already receiving and tolerant to around-the-clock opioid therapy for their underlying persistent cancer pain.
100 mg to 300 mg orally once daily with food. Initiate at 100 mg daily and titrate up by 100 mg increments every 4-7 days based on tolerability. Maximum dose 300 mg daily.
For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.
Terminal elimination half-life: 3-4 hours for tramadol, 5-9 hours for M1 metabolite; clinically, dosing interval is 4-6 hours
Terminal elimination half-life: 6-10 hours (mean 8 hours); prolonged in elderly and hepatic impairment
Tramadol: hepatic via CYP2D6 and CYP3A4 to active M1 metabolite; acetaminophen: hepatic via conjugation (glucuronidation, sulfation) and CYP2E1 (minor).
Hepatic metabolism primarily via CYP3A4; major metabolites include norfentanyl (inactive) and other minor metabolites.
~60% renal (unchanged drug and glucuronide conjugates), ~35% fecal
Renal: ~70% as metabolites (primarily fentanyl conjugates and norfentanyl), ~10% unchanged; Fecal: ~9%; Biliary: minimal
~20% bound to plasma proteins (primarily albumin)
80-85% bound primarily to albumin and alpha-1-acid glycoprotein
3.9 L/kg (tramadol), indicating extensive tissue distribution
4-6 L/kg; large Vd indicates extensive tissue distribution
Oral: 75% (immediate-release); extended-release: ~100% relative to immediate-release
Sublingual: 70-90% (mean 80%); buccal: 50-65%; oral: ~30% due to first-pass metabolism
For creatinine clearance (Cr Cl) 60-89 m L/min: no adjustment. For Cr Cl 30-59 m L/min: reduce dose by 30% (e.g., start 70 mg daily). For Cr Cl 15-29 m L/min: reduce dose by 50% (e.g., start 50 mg daily). For Cr Cl <15 m L/min: not recommended. Hemodialysis: administer dose after dialysis on dialysis days; reduce dose by 70%.
No specific GFR-based dose adjustment recommended; use caution in severe renal impairment (Cr Cl <30 m L/min) due to potential accumulation of fentanyl.
For Child-Pugh Class A (mild): no adjustment. For Child-Pugh Class B (moderate): reduce dose by 50% (e.g., start 50 mg daily). For Child-Pugh Class C (severe): not recommended (or maximum 50 mg daily with caution).
For Child-Pugh Class A or B: no adjustment required; for Child-Pugh Class C: reduce dose and monitor closely for toxicity due to reduced clearance.
Safety and efficacy not established in pediatric patients (<18 years). No recommended dosage.
Not approved for pediatric patients <18 years; safety and efficacy not established.
For patients ≥65 years: initiate at 100 mg daily. Use caution and monitor for confusion and sedation. Consider reducing dose to 50 mg daily if tolerability issues arise.
Initiate at the lowest available dose (100 mcg) and titrate cautiously; elderly patients may have altered pharmacokinetics and increased sensitivity to fentanyl.
Addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion (especially in children); ultra-rapid metabolism of tramadol to O-desmethyltramadol (M1) in CYP2D6 poor metabolizers leading to toxicity; neonatal opioid withdrawal syndrome with prolonged use during pregnancy; risks from concomitant use with benzodiazepines or other CNS depressants.
Risk of respiratory depression, addiction, abuse, and misuse; risk of accidental ingestion; risk of medication errors resulting in fatal overdose; life-threatening respiratory depression in opioid-non-tolerant patients; risk of opioid analgesic drug interactions with CNS depressants; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy.
Respiratory depression; seizure risk (especially with CNS depressants, MAOIs, SSRIs, SNRIs); serotonin syndrome; increased intracranial pressure; severe hypotension; head injury; acute abdominal conditions; renal/hepatic impairment; elderly; debilitated patients; drug dependence; withdrawal; pregnancy; nursing mothers; CYP2D6 ultrarapid metabolizers; concomitant use with alcohol or other CNS depressants.
Respiratory depression, QT prolongation, serotonin syndrome, adrenal insufficiency, severe hypotension, seizures, biliary tract disease, gastrointestinal obstruction, withdrawal syndrome, and risk of overdose with alcohol or other CNS depressants.
Hypersensitivity to tramadol, acetaminophen, or any component; significant respiratory depression; acute or severe bronchial asthma; gastrointestinal obstruction (including paralytic ileus); use of MAOIs within 14 days; treatment of acute severe asthma exacerbation; concurrent use of linezolid; known history of prolonged QT interval or QT prolongation risk factors (tramadol component); severe hepatic impairment (acetaminophen).
Hypersensitivity to fentanyl or any components; opioid-non-tolerant patients; acute or severe bronchial asthma; known or suspected gastrointestinal obstruction; concurrent use of MAOIs or within 14 days of discontinuation.
Grapefruit and grapefruit juice may increase tramadol levels by inhibiting CYP3A4 metabolism. Avoid excessive caffeine as it may increase seizure risk. Food does not significantly affect absorption; may be taken with or without food.
Avoid grapefruit and grapefruit juice during treatment as they inhibit CYP3A4, increasing fentanyl exposure. No other significant food interactions; however, avoid alcohol due to additive CNS depressant effects. Maintain consistent meal timing relative to dosing to minimize variability.
CONZIP (tramadol hydrochloride) is FDA Pregnancy Category C. In first trimester, cross-reactivity with opioid receptors raises concern for neural tube defects based on animal studies; human data limited but not excluded. In second and third trimesters, prolonged use may cause fetal opioid dependence and neonatal abstinence syndrome (NAS). Near term, use may lead to respiratory depression in the neonate.
FDA Pregnancy Category C. First trimester: Inadequate human data; opioid analgesics are not associated with major malformations but may cause neural tube defects at high doses in animal studies. Second trimester: No specific malformation risk. Third trimester: Prolonged use can cause neonatal opioid withdrawal syndrome (NOWS) and respiratory depression at birth.
Tramadol is excreted into breast milk. M/P ratio approximately 0.94 for tramadol and 0.8 for O-desmethyltramadol (active metabolite). Infant exposure estimated at 2.24% of maternal weight-adjusted dose. May cause drowsiness or poor feeding in infants; not recommended during breastfeeding unless benefit outweighs risk.
Minimal excretion into breast milk; M/P ratio not reported. Fentanyl is poorly absorbed orally, making significant infant exposure unlikely. Monitor infant for sedation, respiratory depression, and poor feeding. Avoid use in breastfeeding mothers with opioid dependence or high doses.
No specific dose adjustment guidelines; pregnancy may increase clearance of tramadol, potentially reducing efficacy, but safety data insufficient to recommend dose increase. Use lowest effective dose for shortest duration. Chronic use may require slow taper to prevent withdrawal.
Pregnancy increases clearance and volume of distribution, potentially reducing drug levels. Dose adjustments may be needed: initiate with lower doses and titrate to effect; consider increasing frequency or using breakthrough doses. Monitor for inadequate analgesia. Avoid abrupt discontinuation; taper if stopping.
CONZIP (tramadol hydrochloride) is a centrally acting opioid analgesic with additional serotonin and norepinephrine reuptake inhibition. It has a lower risk of respiratory depression compared to typical opioids but carries risks of seizures, especially in patients with epilepsy, head trauma, or those taking SSRIs, SNRIs, or MAOIs. CYP2D6 poor metabolizers may have reduced efficacy. Do not exceed 400 mg/day (300 mg in elderly >75 years). Avoid sudden discontinuation to prevent withdrawal syndrome.
ABSTRAL (fentanyl sublingual spray) is a transmucosal immediate-release fentanyl (TIRF) formulation indicated for breakthrough pain in opioid-tolerant patients. Due to high bioavailability (~70%) and rapid onset (peak plasma concentration at 15-30 minutes), initial titration must start with 100 mcg, with dose escalation based on efficacy and tolerability. Weight-based conversion from other fentanyl products is not valid; utilize the provided conversion table. Patients must have a rescue agent (e.g., naloxone) available. Concomitant use with CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) or inducers (e.g., rifampin, carbamazepine) requires dose adjustment. Avoid use in opioid-naïve patients due to risk of respiratory depression.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Avoid alcohol, sedatives, and other CNS depressants as they increase risk of severe drowsiness and respiratory depression.,Do not stop suddenly; taper dose under medical supervision to prevent withdrawal symptoms.,May cause dizziness or drowsiness; avoid driving or operating machinery until you know how you react.,Risk of serotonin syndrome when combined with other serotonergic drugs; report symptoms like agitation, high fever, or muscle twitching.,If you have a history of seizures, inform your doctor; tramadol may lower seizure threshold.,Swallow tablets whole; do not crush, chew, or split extended-release tablets.,Store in original container away from moisture and heat.
Use only for breakthrough cancer pain while on around-the-clock opioid therapy.,Do not switch from other fentanyl products based on dose; follow specific conversion instructions.,Spray entire dose into mouth; do not swallow or rinse for at least 10 minutes.,Store at room temperature, away from children and pets.,Dispose of unused units via drug take-back program or by flushing down toilet per FDA guidelines.,Never share this medication with others; death may occur.,Seek emergency if severe drowsiness, confusion, or slow breathing occurs.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CONZIP vs ABSTRAL, answered by our medical review team.
CONZIP is a Opioid Analgesic that works by Tramadol hydrochloride (opioid agonist) and acetaminophen (centrally acting analgesic). Tramadol binds to mu-opioid receptors and inhibits serotonin and norepinephrine reuptake; acetaminophen inhibits cyclooxygenase (COX) and activates descending serotonergic pathways.. ABSTRAL is a Opioid Analgesic that works by Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CONZIP and ABSTRAL depend on the specific clinical indication. These are both Opioid Analgesic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CONZIP is: 100 mg to 300 mg orally once daily with food. Initiate at 100 mg daily and titrate up by 100 mg increments every 4-7 days based on tolerability. Maximum dose 300 mg daily.. The standard adult dose of ABSTRAL is: For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CONZIP and ABSTRAL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CONZIP is classified as Category C. CONZIP (tramadol hydrochloride) is FDA Pregnancy Category C. In first trimester, cross-reactivity with opioid receptors raises concern for neural tube defects based on animal studi. ABSTRAL is classified as Category C. FDA Pregnancy Category C. First trimester: Inadequate human data; opioid analgesics are not associated with major malformations but may cause neural tube defects at high doses in a. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.